A fantastic week for the Precision-Panc platform with the PRIMUS 002 trial opening to recruitment in Glasgow.
PRIMUS 002 is a study for pancreatic patients whose tumour has not spread outside the pancreas and who may be suitable for surgery
The trial will give the patients either FOLFOX-A or AG chemotherapy prior to surgery, hoping to shrink the tumour and ensure all the disease can be removed at time of surgery. The study will also do vital translational work to generate further knowledge on which types of tumour respond better to which treatments.
Study Chief Investigator Derek Grose said “The PRIMUS 002 trial is an exciting and very important step in Pancreatic Cancer research. This study will give vital information on the best way to treat patients with potentially operable Pancreatic Cancer in the future in attempt to improve the very poor outcomes that are currently seen.”
Over the next year PRIMUS 002 will open an further sites around the U.K. Please contact the Precision-Panc team for further information.